Morphic Therapeutic, Inc.

A year or so after getting the green light in the US for Omvoh in ulcerative colitis (UC), Eli Lilly has secured approval in a second major type of inflammatory bowel disease (IBD) for the IL-23 inhib

In Vivo’s editors, along with experts from the wider Citeline team, have selected our top four picks for the most significant M&A, alliance and financing deals of 2024. Vote now in the polls belo

Eli Lilly is relatively young in immunology, but it has demonstrated a strategic commitment to growing its pipeline and presence in rheumatologic, dermatologic and gastroenterologic indications. Its f

With the business year almost complete, a review of biopharmaceutical dealmaking showed that Novartis, in particular, enjoyed a very productive year with 21 transactions overall, including six acquisi